MedPath

Early rhBNP on Myocardial Remodeling and Reperfusion in Patients With STEMI

Phase 4
Recruiting
Conditions
ST Segment Elevated Myocardial Infarction
Interventions
Drug: Control
Registration Number
NCT04033861
Lead Sponsor
RenJi Hospital
Brief Summary

The study intends to evaluate the efficacy of early rhBNP on myocardial remodeling and reperfusion in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention

Detailed Description

As prospectively observational study,it brings anterior acute myocardial infarct patients from 2018 JAN. to 2019 JAN, whose predefined time between symptom onset and percutaneous is not more than 12 hours. The door-to-balloon time, present to balloon time and first medical contact-to-balloon time will be documented. ECG in FMC and 90min after PCI also will be record. Patients assigned to the rhBNP group will receive intravenous rhBNP before PCI,and the variety of heart rate and blood pressure will be record. Routinely evaluation of corrected TIMI frame counting(CTFC), TIMI myocardial perfusion frame counting and TIMI myocardial perfusion grade(TMPG).Blood tests including BNP, CK-MB and CRP are measured at admission and6, 12, 24, 48 hours after PCI. Both Cardiovascular magnetic imaging and echocardiography will be applied in Day 30 and 12 months. The composite endpoint is incidence of all-cause mortality, reinfarct, stroke and target vessel revascularization at hospitalization and follow-up. Principally patients are prevented from any drug affecting microcirculation (GPIIb/IIa receptor agonist, vascular dilation drug, etc.), otherwise it is necessary, which should be documented.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
352
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
rhBNPrhBNPrhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
ControlControlsaline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour after randomization.
Primary Outcome Measures
NameTimeMethod
Compound endpoints of epicardium and endocardium perfusion90min after infarct related artery revascularization

Both the TIMI and TMPG score reach 3 immediately after PCI, besides ST resolution≥70% at 90min after PCI.

Secondary Outcome Measures
NameTimeMethod
ST-segment Resolution90 mins after PCI

Resolution of the initial sum of ST-segment elevation ≥ 70%

Wall motion score index (WMSI) and LVEF by echocardiographyDay 1, 3, 7, 30 and 12 month after PCI

Echocardiographic index includes WMSI and LVEF

TIMI Flow Grade (TFG)One mins after PCI

TIMI Flow Grade (TFG)assesses flow in the epicardial arteries

TIMI Frame Count (CTFC)One mins after PCI

CTFC is a continuous measurement assessing flow in the epicardial arteries.

TIMI Myocardial Perfusion Grade (TMPG)One mins after PCI

TMPG is an angiographic measure of myocardial perfusion

TIMI Myocardial Perfusion Frame Count (TMPFC)One mins after PCI

TMPFC is a novel method to standardize and quantify myocardial perfusion by timing the filling and washout of contrast in the myocardium using cine-angiographic frame-counting. Briefly, the first frame of TMPFC was defined as the frame that clearly demonstrated the first appearance of myocardial blush beyond the IRA (F1). The last frame of TMPFC was then defined as the frame where contrast or myocardial blush disappeared (F2). TMPFC is F2-F1 frame counts at a filming rate of 15 frames/sec, or (F2-F1)×2 frame counts at the corrected filming rate of 30 frames/sec

CMR imagingDay 1, 3, 7, 30 and 12 month after PCI

CMR imaging will be collected using a 3.0-Tesla-scanner (Achieva, Philips Healthcare, The Netherlands) under electrocardiogram-triggered gating in School Shanghai Jiaotong University school of medicine RenJi hospital.

Trial Locations

Locations (1)

Ren Ji Hospital Afflited to School of Medicine, Shanghai Jiao Tong University

🇨🇳

Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath